Septerna, Inc. Research and Development Expense
Septerna, Inc. (SEPN) reported Research and Development Expense of $35.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Septerna, Inc. research and development expense for the quarter ending 2026-06-30 was $35.13M, a 58.34% increase year-over-year.
- Septerna, Inc. research and development expense for the quarter ending 2026-03-31 was $29.54M, a 53.26% increase year-over-year.
- Septerna, Inc. research and development expense for the quarter ending 2025-12-31 was $31.86M, a 64.94% increase year-over-year.
- Septerna, Inc. research and development expense for the quarter ending 2025-09-30 was $24.26M, a 36.07% increase year-over-year.
- Septerna, Inc. research and development expense for fiscal 2025 was $97.58M, a 49.35% increase from fiscal 2024.
- Septerna, Inc. research and development expense for fiscal 2024 was $65.34M, a 81.60% increase from fiscal 2023.
- Septerna, Inc. research and development expense for fiscal 2023 was $35.98M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.13M 10-Q · filed 2026-08-10 | $64.67M 10-Q · filed 2026-08-10 | $96.53M derived: sum of 3 quarters · filed 2026-08-10 | $120.79M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $29.54M 10-Q · filed 2026-05-11 | $61.40M derived: sum of 2 quarters · filed 2026-05-11 | $85.66M derived: sum of 3 quarters · filed 2026-05-11 | $107.85M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $31.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $56.13M derived: sum of 2 quarters · filed 2026-03-09 | $78.31M derived: sum of 3 quarters · filed 2026-08-10 | $97.58M 10-K · filed 2026-03-09 |
| 2025-09-30 | $24.26M 10-Q · filed 2025-11-10 | $46.45M derived: sum of 2 quarters · filed 2026-08-10 | $65.72M 10-Q · filed 2025-11-10 | $85.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $22.19M 10-Q · filed 2026-08-10 | $41.46M 10-Q · filed 2026-08-10 | $60.78M derived: sum of 3 quarters · filed 2026-08-10 | $78.61M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $19.27M 10-Q · filed 2026-05-11 | $38.59M derived: sum of 2 quarters · filed 2026-05-11 | $56.42M derived: sum of 3 quarters · filed 2026-05-11 | $71.45M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $19.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $37.15M derived: sum of 2 quarters · filed 2026-03-09 | $52.18M derived: sum of 3 quarters · filed 2026-03-09 | $65.34M 10-K · filed 2026-03-09 |
| 2024-09-30 | $17.83M 10-Q · filed 2025-11-10 | $32.87M derived: sum of 2 quarters · filed 2025-11-10 | $46.02M 10-Q · filed 2025-11-10 | $56.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $15.04M 10-Q · filed 2025-08-11 | $28.19M 10-Q · filed 2025-08-11 | $38.51M derived: sum of 3 quarters · filed 2025-08-11 | $47.80M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $13.15M 10-Q · filed 2025-05-15 | $23.48M derived: sum of 2 quarters · filed 2025-05-15 | $32.76M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $10.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $19.61M derived: sum of 2 quarters · filed 2025-03-27 | $35.98M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $9.28M 10-Q · filed 2024-11-20 | $25.65M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |